Chelsea K Meenan1, John A Kelly1, Li Wang2, A Kim Ritchey3, Scott H Maurer2,3. 1. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 2. Clinical and Translational Sciences Institute, University of Pittsburgh, Pittsburgh, Pennsylvania. 3. Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
PURPOSE: Obesity correlates with adverse events (AEs) in children with acute myelogenous leukemia and during maintenance therapy for acute lymphoblastic leukemia (ALL). Less is known about AEs in obese ALL patients during pre-maintenance chemotherapy. We evaluated the relationship between obesity (body mass index (BMI) ≥ 95th percentile) and AEs during pre-maintenance chemotherapy in pediatric patients with ALL. METHODS: One hundred fifty-five pediatric ALL patients diagnosed at a single institution between 2006 and 2012 were retrospectively evaluated for infections, treatment-requiring hypertension, insulin-requiring hyperglycemia, pancreatitis, pediatric intensive care unit admissions, sepsis, febrile neutropenia (FN) admissions, thrombosis, hepatotoxicity, and nephrotoxicity. Univariate and multivariable analyses compared proportions of obese versus nonobese patients experiencing AEs. RESULTS: AEs occurring significantly more frequently in obese patients by univariate analysis included treatment-requiring hypertension (17.5% vs 6.1%; OR, 3.27; 95% CI, 1.1-10.0, P = 0.0497) and insulin-requiring hyperglycemia (25.0% vs 11.3%; OR, 2.62; 95% CI, 1.04-6.56, P = 0.04). Obese patients had greater incidence rates for recurrent admission-requiring infections (incidence rate ratio (IRR) 1.64; 95% CI, 1.08-2.48, P = 0.02) and recurrent FN admissions (IRR, 1.53; 95% CI, 1.10-2.12, P = 0.01). Accounting for combined age and NCI risk status, obesity was a risk factor for treatment-requiring hypertension (OR, 3.90; 95% CI, 1.19-12.76, P = 0.02), insulin-requiring hyperglycemia (OR, 3.92; 95% CI, 1.39-11.05, P = 0.01), and FN admission (OR, 2.92; 95% CI, 1.27-6.73, P = 0.01). CONCLUSIONS: During pre-maintenance chemotherapy for ALL, obesity is a risk factor for the development of hypertension, hyperglycemia, and FN admissions. This research provides implications for augmented preventive and supportive care guidelines in obese ALL patients.
PURPOSE:Obesity correlates with adverse events (AEs) in children with acute myelogenous leukemia and during maintenance therapy for acute lymphoblastic leukemia (ALL). Less is known about AEs in obese ALL patients during pre-maintenance chemotherapy. We evaluated the relationship between obesity (body mass index (BMI) ≥ 95th percentile) and AEs during pre-maintenance chemotherapy in pediatric patients with ALL. METHODS: One hundred fifty-five pediatric ALL patients diagnosed at a single institution between 2006 and 2012 were retrospectively evaluated for infections, treatment-requiring hypertension, insulin-requiring hyperglycemia, pancreatitis, pediatric intensive care unit admissions, sepsis, febrile neutropenia (FN) admissions, thrombosis, hepatotoxicity, and nephrotoxicity. Univariate and multivariable analyses compared proportions of obese versus nonobesepatients experiencing AEs. RESULTS:AEs occurring significantly more frequently in obesepatients by univariate analysis included treatment-requiring hypertension (17.5% vs 6.1%; OR, 3.27; 95% CI, 1.1-10.0, P = 0.0497) and insulin-requiring hyperglycemia (25.0% vs 11.3%; OR, 2.62; 95% CI, 1.04-6.56, P = 0.04). Obesepatients had greater incidence rates for recurrent admission-requiring infections (incidence rate ratio (IRR) 1.64; 95% CI, 1.08-2.48, P = 0.02) and recurrent FN admissions (IRR, 1.53; 95% CI, 1.10-2.12, P = 0.01). Accounting for combined age and NCI risk status, obesity was a risk factor for treatment-requiring hypertension (OR, 3.90; 95% CI, 1.19-12.76, P = 0.02), insulin-requiring hyperglycemia (OR, 3.92; 95% CI, 1.39-11.05, P = 0.01), and FN admission (OR, 2.92; 95% CI, 1.27-6.73, P = 0.01). CONCLUSIONS: During pre-maintenance chemotherapy for ALL, obesity is a risk factor for the development of hypertension, hyperglycemia, and FN admissions. This research provides implications for augmented preventive and supportive care guidelines in obese ALL patients.
Authors: Etan Orgel; Richard Sposto; Jemily Malvar; Nita L Seibel; Elena Ladas; Paul S Gaynon; David R Freyer Journal: J Clin Oncol Date: 2014-03-31 Impact factor: 44.544
Authors: Gregory T Armstrong; Kevin C Oeffinger; Yan Chen; Toana Kawashima; Yutaka Yasui; Wendy Leisenring; Marilyn Stovall; Eric J Chow; Charles A Sklar; Daniel A Mulrooney; Ann C Mertens; William Border; Jean-Bernard Durand; Leslie L Robison; Lillian R Meacham Journal: J Clin Oncol Date: 2013-09-03 Impact factor: 44.544
Authors: P de Laat; M L Te Winkel; A S Devos; C E Catsman-Berrevoets; R Pieters; M M van den Heuvel-Eibrink Journal: Ann Oncol Date: 2010-08-10 Impact factor: 32.976
Authors: Rona Y Sonabend; Siripoom V McKay; M Fatih Okcu; Jinrong Yan; Morey W Haymond; Judith F Margolin Journal: Pediatr Blood Cancer Date: 2008-09 Impact factor: 3.167
Authors: M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: Gilbert P August; Sonia Caprio; Ilene Fennoy; Michael Freemark; Francine R Kaufman; Robert H Lustig; Janet H Silverstein; Phyllis W Speiser; Dennis M Styne; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2008-09-09 Impact factor: 5.958
Authors: Taumoha Ghosh; Michaela Richardson; Peter M Gordon; Justin R Ryder; Logan G Spector; Lucie M Turcotte Journal: Cancer Med Date: 2020-07-24 Impact factor: 4.452